"The deal, which includes Eli Lilly and Novo Nordisk, will slash prices for Medicare and Medicaid programme recipients. United States President Donald Trump, Eli Lilly and Novo Nordisk have unveiled a deal to slash the prices of popular GLP-1 weightloss drugs for the government's Medicare and Medicaid programme, as well as for cash payers. The deal, announced on Thursday, is aimed at increasing access to treatments through US Medicare for people aged 65 and above and the Medicaid programme for low-income people,"
"Starter doses of rival weightloss pills being developed by Lilly and Novo, if approved, will cost $149 per month for all Medicare and Medicaid enrollees and via the White House's new direct-to-consumer site, TrumpRx, senior administration officials said. For currently available injectable GLP-1s used for diabetes and other covered health issues, prices would fall to $245 per month for patients with Medicare or Medicaid, they said."
An agreement between the US government, Eli Lilly and Novo Nordisk will sharply lower prices for popular GLP-1 weight-loss drugs for Medicare, Medicaid and cash-paying patients. Starter doses of rival pills, if approved, will cost $149 per month for Medicare and Medicaid enrollees and via TrumpRx. Currently available injectable GLP-1s used for diabetes and other covered conditions would fall to $245 per month for Medicare or Medicaid patients, with TrumpRx prices starting at or below $350 and expected to drop to $245 within two years. Zepbound's lowest dose will be $299 monthly for cash payers, with higher doses at $449. Medicare co-pays will be capped at $50 per month.
Read at www.aljazeera.com
Unable to calculate read time
Collection
[
|
...
]